Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 25

1.

Reply to Theilacker et al.

Naucler P, Galanis I, Morfeldt E, Darenberg J, Örtqvist Å, Henriques-Normark B.

Clin Infect Dis. 2018 May 2;66(10):1642-1643. doi: 10.1093/cid/cix1115. No abstract available.

PMID:
29272334
2.

Comparison of the Impact of Pneumococcal Conjugate Vaccine 10 or Pneumococcal Conjugate Vaccine 13 on Invasive Pneumococcal Disease in Equivalent Populations.

Naucler P, Galanis I, Morfeldt E, Darenberg J, Örtqvist Å, Henriques-Normark B.

Clin Infect Dis. 2017 Nov 13;65(11):1780-1789. doi: 10.1093/cid/cix685. Erratum in: Clin Infect Dis. 2019 Jan 18;68(3):534.

3.

Pneumococcal Carriage in Children under Five Years in Uganda-Will Present Pneumococcal Conjugate Vaccines Be Appropriate?

Lindstrand A, Kalyango J, Alfvén T, Darenberg J, Kadobera D, Bwanga F, Peterson S, Henriques-Normark B, Källander K.

PLoS One. 2016 Nov 9;11(11):e0166018. doi: 10.1371/journal.pone.0166018. eCollection 2016.

4.

Unaltered pneumococcal carriage prevalence due to expansion of non-vaccine types of low invasive potential 8years after vaccine introduction in Stockholm, Sweden.

Lindstrand A, Galanis I, Darenberg J, Morfeldt E, Naucler P, Blennow M, Alfvén T, Henriques-Normark B, Örtqvist Å.

Vaccine. 2016 Aug 31;34(38):4565-4571. doi: 10.1016/j.vaccine.2016.07.031. Epub 2016 Jul 26.

5.

Effects of PCV7 and PCV13 on invasive pneumococcal disease and carriage in Stockholm, Sweden.

Galanis I, Lindstrand A, Darenberg J, Browall S, Nannapaneni P, Sjöström K, Morfeldt E, Naucler P, Blennow M, Örtqvist Å, Henriques-Normark B.

Eur Respir J. 2016 Apr;47(4):1208-18. doi: 10.1183/13993003.01451-2015. Epub 2016 Jan 21.

6.

Clinical manifestations of invasive pneumococcal disease by vaccine and non-vaccine types.

Browall S, Backhaus E, Naucler P, Galanis I, Sjöström K, Karlsson D, Berg S, Luthander J, Eriksson M, Spindler C, Ejdebäck M, Trollfors B, Darenberg J, Kalin M, Örtqvist A, Andersson R, Henriques-Normark B.

Eur Respir J. 2014 Dec;44(6):1646-57. doi: 10.1183/09031936.00080814. Epub 2014 Oct 16.

7.

Reply to Arends and Harkisoen.

Linnér A, Sjölin J, Darenberg J, Henriques-Normark B, Norrby-Teglund A.

Clin Infect Dis. 2015 Jan 15;60(2):324-5. doi: 10.1093/cid/ciu800. Epub 2014 Oct 13. No abstract available.

8.

Clinical efficacy of polyspecific intravenous immunoglobulin therapy in patients with streptococcal toxic shock syndrome: a comparative observational study.

Linnér A, Darenberg J, Sjölin J, Henriques-Normark B, Norrby-Teglund A.

Clin Infect Dis. 2014 Sep 15;59(6):851-7. doi: 10.1093/cid/ciu449. Epub 2014 Jun 13.

PMID:
24928291
9.

Evolutionary pathway to increased virulence and epidemic group A Streptococcus disease derived from 3,615 genome sequences.

Nasser W, Beres SB, Olsen RJ, Dean MA, Rice KA, Long SW, Kristinsson KG, Gottfredsson M, Vuopio J, Raisanen K, Caugant DA, Steinbakk M, Low DE, McGeer A, Darenberg J, Henriques-Normark B, Van Beneden CA, Hoffmann S, Musser JM.

Proc Natl Acad Sci U S A. 2014 Apr 29;111(17):E1768-76. doi: 10.1073/pnas.1403138111. Epub 2014 Apr 14.

10.

[Increase in serious infections due to group A streptococci].

Glans H, Rönnbäck K, Berggren I, Darenberg J, Linde A, Eriksson BK.

Lakartidningen. 2013 May 29-Jun 4;110(22):1094-7. Review. Swedish. No abstract available.

PMID:
23808080
11.

Increased incidence of invasive group A streptococcal infections in Sweden, January 2012-February 2013.

Darenberg J, Henriques-Normark B, Lepp T, Tegmark-Wisell K, Tegnell A, Widgren K.

Euro Surveill. 2013 Apr 4;18(14):20443.

12.

Contribution of host, bacterial factors and antibiotic treatment to mortality in adult patients with bacteraemic pneumococcal pneumonia.

Naucler P, Darenberg J, Morfeldt E, Ortqvist A, Henriques Normark B.

Thorax. 2013 Jun;68(6):571-9. doi: 10.1136/thoraxjnl-2012-203106. Epub 2013 Feb 26.

PMID:
23442364
13.

Improvement of CRB-65 as a prognostic scoring system in adult patients with bacteraemic pneumococcal pneumonia.

Dwyer R, Hedlund J, Darenberg J, Henriques-Normark B, Naucler P, Runesdotter S, Kalin M.

Scand J Infect Dis. 2011 Jul;43(6-7):448-55. doi: 10.3109/00365548.2011.562529. Epub 2011 Mar 3.

PMID:
21370939
14.

The epidemiology of pneumococcal infections--the Swedish experience.

Darenberg J, Henriques Normark B.

Vaccine. 2009 Dec 30;27 Suppl 6:G27-32. doi: 10.1016/j.vaccine.2009.10.088.

PMID:
20006136
15.

Severe group A streptococcal infections in Uppsala County, Sweden: clinical and molecular characterization of a case cluster from 2006 to 2007.

Vikerfors A, Haggar A, Darenberg J, Low A, Melhus A, Hedlund J, Sylvan S, Norrby-Teglund A, Eriksson BM.

Scand J Infect Dis. 2009;41(11-12):823-30. doi: 10.3109/00365540903179749.

PMID:
19922064
16.

Bacterial phenotype variants in group B streptococcal toxic shock syndrome.

Sendi P, Johansson L, Dahesh S, Van-Sorge NM, Darenberg J, Norgren M, Sjölin J, Nizet V, Norrby-Teglund A.

Emerg Infect Dis. 2009 Feb;15(2):223-32.

17.

Clinical and microbiological characteristics of severe Streptococcus pyogenes disease in Europe.

Luca-Harari B, Darenberg J, Neal S, Siljander T, Strakova L, Tanna A, Creti R, Ekelund K, Koliou M, Tassios PT, van der Linden M, Straut M, Vuopio-Varkila J, Bouvet A, Efstratiou A, Schalén C, Henriques-Normark B; Strep-EURO Study Group, Jasir A.

J Clin Microbiol. 2009 Apr;47(4):1155-65. doi: 10.1128/JCM.02155-08. Epub 2009 Jan 21.

18.

Epidemiology of severe Streptococcus pyogenes disease in Europe.

Lamagni TL, Darenberg J, Luca-Harari B, Siljander T, Efstratiou A, Henriques-Normark B, Vuopio-Varkila J, Bouvet A, Creti R, Ekelund K, Koliou M, Reinert RR, Stathi A, Strakova L, Ungureanu V, Schalén C; Strep-EURO Study Group, Jasir A.

J Clin Microbiol. 2008 Jul;46(7):2359-67. doi: 10.1128/JCM.00422-08. Epub 2008 May 7.

19.

Soluble M1 protein of Streptococcus pyogenes triggers potent T cell activation.

Påhlman LI, Olin AI, Darenberg J, Mörgelin M, Kotb M, Herwald H, Norrby-Teglund A.

Cell Microbiol. 2008 Feb;10(2):404-14. Epub 2007 Sep 28.

PMID:
17900297
20.

Molecular and clinical characteristics of invasive group A streptococcal infection in Sweden.

Darenberg J, Luca-Harari B, Jasir A, Sandgren A, Pettersson H, Schalén C, Norgren M, Romanus V, Norrby-Teglund A, Normark BH.

Clin Infect Dis. 2007 Aug 15;45(4):450-8. Epub 2007 Jul 10.

PMID:
17638193
21.

A food-borne streptococcal sore throat outbreak in a small community.

Asteberg I, Andersson Y, Dotevall L, Ericsson M, Darenberg J, Henriques-Nordmark B, Söderström A.

Scand J Infect Dis. 2006;38(11-12):988-94.

PMID:
17148066
22.

Variations in emm type among group A streptococcal isolates causing invasive or noninvasive infections in a nationwide study.

Ekelund K, Darenberg J, Norrby-Teglund A, Hoffmann S, Bang D, Skinhøj P, Konradsen HB.

J Clin Microbiol. 2005 Jul;43(7):3101-9.

23.

Differences in potency of intravenous polyspecific immunoglobulin G against streptococcal and staphylococcal superantigens: implications for therapy of toxic shock syndrome.

Darenberg J, Söderquist B, Normark BH, Norrby-Teglund A.

Clin Infect Dis. 2004 Mar 15;38(6):836-42. Epub 2004 Mar 1.

PMID:
14999628
24.

Intravenous immunoglobulin adjunctive therapy in sepsis, with special emphasis on severe invasive group A streptococcal infections.

Norrby-Teglund A, Ihendyane N, Darenberg J.

Scand J Infect Dis. 2003;35(9):683-9. Review.

PMID:
14620155
25.

Intravenous immunoglobulin G therapy in streptococcal toxic shock syndrome: a European randomized, double-blind, placebo-controlled trial.

Darenberg J, Ihendyane N, Sjölin J, Aufwerber E, Haidl S, Follin P, Andersson J, Norrby-Teglund A; StreptIg Study Group.

Clin Infect Dis. 2003 Aug 1;37(3):333-40. Epub 2003 Jul 17.

PMID:
12884156

Supplemental Content

Loading ...
Support Center